Across TCGA pan-cancer cohorts, CTAGE15 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CTAGE15 data layer compared with 17 for mass-spec protein.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher CTAGE15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CTAGE15 expression acts as an unfavorable survival marker.
GBM are the cancer types where CTAGE15 Mutation most reproducibly stratifies survival.